Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Neurogene Inc. Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates August 09, 2024 From Neurogene Inc. Via Business Wire Tickers NGNE Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome August 07, 2024 From Neurogene Inc. Via Business Wire Tickers NGNE Neurogene to Participate in BMO Genetic Medicines Summit July 02, 2024 From Neurogene Inc. Via Business Wire Tickers NGNE Neurogene Announces Addition to Russell 3000® Index July 01, 2024 From Neurogene Inc. Via Business Wire Tickers NGNE Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome June 18, 2024 From Neurogene Inc. Via Business Wire Tickers NGNE Neurogene to Participate in Upcoming Conferences June 05, 2024 From Neurogene Inc. Via Business Wire Tickers NGNE Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program June 03, 2024 From Neurogene Inc. Via Business Wire Tickers NGNE Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates May 10, 2024 From Neurogene Inc. Via Business Wire Tickers NGNE Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting May 07, 2024 From Neurogene Inc. Via Business Wire Tickers NGNE Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting April 22, 2024 From Neurogene Inc. Via Business Wire Tickers NGNE Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates March 18, 2024 From Neurogene Inc. Via Business Wire Tickers NGNE Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial March 04, 2024 From Neurogene Inc. Via Business Wire Tickers NGNE Neurogene to Participate in Upcoming Investor Conferences February 29, 2024 From Neurogene Inc. Via Business Wire Tickers NGNE Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer January 16, 2024 From Neurogene Inc. Via Business Wire Tickers NGNE Neurogene Announces Business Update and 2024 Outlook January 05, 2024 From Neurogene Inc. Via Business Wire Tickers NGNE Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million December 19, 2023 From Neurogene Inc. Via Business Wire Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome November 30, 2023 From Neurogene Inc. Via Business Wire Neurogene Announces FDA Clearance of IND for NGN-401 Gene Therapy for Children with Rett Syndrome January 23, 2023 From Neurogene Inc. Via Business Wire Neurogene Announces New Development Program in Rett Syndrome Utilizing Novel EXACT Technology Platform May 18, 2022 From Neurogene Inc. Via Business Wire Neurogene Announces FDA Clearance of IND for NGN-101 Gene Therapy to Treat CLN5 Batten Disease September 14, 2021 From Neurogene Inc. Via Business Wire Neurogene Announces EMA Grants Orphan Drug Designation to CLN5 Batten Disease Gene Therapy June 29, 2021 From Neurogene Inc. Via Business Wire Neurogene’s AAV Biodistribution Study Shows Route of Administration Essential Component in Optimizing Gene Therapy Treatment for Neurological Disease May 11, 2021 From Neurogene Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.